Oncology + Obesity

TNIK

CHEMBL4523

IN CRO

33,755 ADMET-validated FIC candidates. Tanimoto < 0.21 vs rentosertib (FTO-clean white-space library).

ADMET Passed

33,755

Pareto Rank 1

1,847

CRO

3 compounds submitted

Stage

First-in-class

Mechanism

TRAF2/NCK-interacting kinase (TNIK) inhibition — Wnt signaling downstream node

Precedent

No approved drug. Rentosertib (Insilico, Phase II NCT05938920) is sole clinical-stage competitor.

Indications

Colorectal cancer · Obesity · Idiopathic pulmonary fibrosis

Milestones

2026-W10

FIC library reached 33,755 compounds — largest FIC TNIK library known

2026-W13

Top-3 compounds submitted to CRO

2026-W17

CRO IC50 + WNT pathway readback expected